Abeona Stock Today

ABEO -  USA Stock  

USD 0.27  0.02  6.90%

Market Performance
0 of 100
Odds Of Distress
Over 93
Abeona Therapeutics is selling for 0.27 as of the 16th of January 2022. This is a -6.9 percent down since the beginning of the trading day. The stock's open price was 0.29. Abeona Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Abeona Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of December 2021 and ending today, the 16th of January 2022. Please note, there could be an existing legal relationship between Abeona Therapeutics (ABEO) and Abeona Therapeutics (AKC). Click here to learn more.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York. Abeona Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 146.62 M outstanding shares of which 1.34 M shares are presently shorted by private and institutional investors with about 1.41 trading days to cover. More on Abeona Therapeutics

Abeona Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Abeona Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Abeona Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Abeona Therapeutics generated a negative expected return over the last 90 days
Abeona Therapeutics has high historical volatility and very poor performance
Abeona Therapeutics has some characteristics of a very speculative penny stock
Abeona Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 3 M. Net Loss for the year was (54.08 M) with loss before overhead, payroll, taxes, and interest of (20.14 M).
Abeona Therapeutics currently holds about 67 M in cash with (37.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.66, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 16.0% of the company shares are held by company insiders
Latest headline from industrialit.com.au: Mucopolysaccharidosis Treatment Market 2022 Global Analysis, Research, Review, Applications and Forecast to 2027 Industrial IT - Industrial IT
Abeona Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Abeona Therapeutics SEC Filings
Abeona Therapeutics SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameAbeona Therapeutics
Related EntityAKC (Abeona Therapeutics)
CEO and President and DirectorTimothy Miller  (View All)
Average Analyst Recommendation
Analysts covering Abeona Therapeutics report their recommendations after researching Abeona Therapeutics' financial statements, talking to executives and customers, or listening in on Abeona Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Abeona Therapeutics. The Abeona consensus assessment is calculated by taking the average forecast from all of the analysts covering Abeona Therapeutics.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Abeona Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Abeona Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 5 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares115 M106.6 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted115 M106.6 M
Significantly Up
Slightly volatile
Net Cash Flow from Operations(34 M)(31.5 M)
Significantly Down
Slightly volatile
Total Assets151.8 M173.9 M
Fairly Down
Slightly volatile
Total Liabilities60.4 M55.9 M
Significantly Up
Slightly volatile
Current Assets96.7 M112.4 M
Fairly Down
Slightly volatile
Current Liabilities52.1 M48.3 M
Significantly Up
Slightly volatile
Total Debt8.6 M10 M
Fairly Down
Slightly volatile
Return on Average Assets(0.65)(0.6)
Significantly Down
Slightly volatile
Gross Margin1.171.15
Fairly Up
Slightly volatile
Asset Turnover0.05730.0558
Fairly Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Abeona Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Abeona Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Abeona Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Abeona Therapeutics' financial leverage. It provides some insight into what part of Abeona Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Abeona Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Abeona Therapeutics deploys its capital and how much of that capital is borrowed.
Abeona Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 6.17 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Abeona Therapeutics has a current ratio of 2.52, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(34.01 Million)Share
Abeona Therapeutics (ABEO) is traded on NASDAQ Exchange in USA. It is located in 1330 Avenue of the Americas, 33rd Floor, New York, NY 10019, United States and employs 76 people. Abeona Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 44.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abeona Therapeutics's market, we take the total number of its shares issued and multiply it by Abeona Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Abeona Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 146.62 M outstanding shares of which 1.34 M shares are presently shorted by private and institutional investors with about 1.41 trading days to cover. Abeona Therapeutics currently holds about 67 M in cash with (37.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.66, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Abeona Therapeutics Probability Of Bankruptcy
Abeona Therapeutics retains a total of 146.62 Million outstanding shares. Abeona Therapeutics shows significant amount of outstanding shares owned by insiders and institutional investors .Since such a large part of the company is not owned by regular investors, we recommend to check if there were significant buying or selling the Abeona Therapeutics stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Abeona Ownership Details

Abeona Stock Price Odds Analysis

What are Abeona Therapeutics' target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Abeona Therapeutics jumping above the current price in 90 days from now is more than 93.0%. The Abeona Therapeutics probability density function shows the probability of Abeona Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.9466. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Abeona Therapeutics will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Abeona Therapeutics is significantly underperforming DOW.
 Odds Down 0.27HorizonTargetOdds Up 0.27 
6.92%90 days
Based on a normal probability distribution, the odds of Abeona Therapeutics to move above the current price in 90 days from now is more than 93.0 (This Abeona Therapeutics probability density function shows the probability of Abeona Stock to fall within a particular range of prices over 90 days) .

Abeona Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Abeona Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Abeona Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Abeona Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Webster Bank N ACommon Shares85.00.0
Adage Capital Partners Gp LlcCommon SharesMM
View Abeona Therapeutics Diagnostics

Abeona Therapeutics Historical Income Statement

Abeona Therapeutics Income Statement is one of the three primary financial statements used for reporting Abeona's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Abeona Therapeutics revenue and expense. Abeona Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Abeona Therapeutics Weighted Average Shares is quite stable at the moment as compared to the past year. The company's current value of Weighted Average Shares is estimated at 114.98 Million. Weighted Average Shares Diluted is expected to rise to about 115 M this year, although the value of Consolidated Income will most likely fall to (77.8 M). View More Fundamentals

Abeona Stock Against Markets

Picking the right benchmark for Abeona Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Abeona Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Abeona Therapeutics is critical whether you are bullish or bearish towards Abeona Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Abeona Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Volatility Now


Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

Abeona Therapeutics Corporate Directors

Abeona Therapeutics corporate directors refer to members of an Abeona Therapeutics board of directors. The board of directors generally takes responsibility for the Abeona Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Abeona Therapeutics' board members must vote for the resolution. The Abeona Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Mark Alvino - Independent DirectorProfile
Mark Ahn - Independent DirectorProfile
Stephen Howell - Independent DirectorProfile
Jeffrey Davis - COO and DirectorProfile
Please continue to Trending Equities. Note that the Abeona Therapeutics information on this page should be used as a complementary analysis to other Abeona Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Abeona Stock analysis

When running Abeona Therapeutics price analysis, check to measure Abeona Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abeona Therapeutics is operating at the current time. Most of Abeona Therapeutics' value examination focuses on studying past and present price action to predict the probability of Abeona Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abeona Therapeutics' price. Additionally, you may evaluate how the addition of Abeona Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is Abeona Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Abeona Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.